Online Consultation For Penile Cancer Treatment Doctors in Spain

Dr. Antonio Alcaraz Asensio is a specialized Urologist in Spain. And one of the most sought after medical specialists in Barcelona, Spain. The doctor has over 36 Years of experience and is associated with Centro Medico Teknon.

Association and Memberships Dr. Antonio Alcaraz Asensio is part of:

• Spanish Association of Urology
• Secretary General of the Spanish Association of Urology (currently)
• Member of the European Association of Urology (EAU)
• Member of the American Urological Association (AUA)
• Member of the Colombian, Dominican and Polish Societies of Urology.

Qualifications :

• Bachelor of Medicine and Surgery at the University of Barcelona (1983)
• Completion of the doctoral thesis at the University of Barcelona (1987)
• Specialization in Urology after residency at Hospital Clinic de Barcelona (1988)
• Research fellow for one year. Subsequently, a second period as an 18-month Research Fellow at the Mayo Clinic in Rochester, Minnesota (1993-1994)

Hospital Address :

Centro M

Medical Expertise of Dr. Antonio Alcaraz Asensio

• Renowned urologist, expert in treating prostate, bladder and kidney cancer, pioneer of laparoscopic and robotic surgery techniques.
• Puigvert Foundation, Barcelona Hospital Clinic, and Research Fellowship in Urology, Mayo Clinic Rochester (Minnesota, USA).
• Member of the European Association of Urology (EAU), Scientific Committee of the European Association of Urology (EAU), and American Urological Association (AUA).
• Research publications in international journals, director of 17 doctoral thesis, and strong teaching experience.

Dr. Joan Carles Galceran is a specialized Medical Oncologist in Spain. And one of the most sought after medical specialists in Barcelona, Spain. The doctor has over 25 Years of experience and is associated with Centro Medico Teknon.

Association and Memberships Dr. Joan Carles Galceran is part of:

• Member of the American Association of Clinical Oncology (ASCO)
• European Association for Medical Oncology (ESMO).
• Spanish Society of Medical Oncology (SEOM).

Certifications :

• He completed his studies by obtaining the European Certificate in Medical Oncology in Vienna in November 1996.

Qualifications :

• Dr. Joan Carles Galceran graduated in Medicine and Surgery at the University of Barcelona in 1987.
• Ph.D., with cum laude, in 1992 from the Autonomous University of Barcelona.

Hospital Address :

Centro M

What is the medical expertise of Dr Joan Carles Galceran?

• With over 25 years of experience, Dr Joan Carles Galceran is a leading oncologist specializing in sarcoma, kidney cancer, bladder cancer, and prostate cancer treatment. His expertise includes immunotherapy and chemotherapy.
• Dr Carles is associated with noteworthy organizations such as the European Society for Medical Oncology(ESMO), the Spanish Society of Head and Neck Tumors(CTT), the Spanish Sarcoma Research Group(GEIS), the American Society of Clinical Oncology(ASCO) and the Spanish Association of Medical Oncology(SEOM). He is the Secretary and Co-founder of the Spanish Oncology Genitourinary Group(SOGUG).
• In 1996, he obtained the European Certificate in Medical Oncology in Vienna.
• Dr Carles has more than 70 peer-reviewed papers to his credit. Some of his publications include:
  1. Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, et al. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer. 2022 Sep;173:317-326.
  2. Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, Semidey ME, Lorente D, Trilla E, Carles J. Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022 Oct 4;12:970199.
  3. Agarwal N, Azad A, Carles J, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198.